Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

13.76 -0.03 (-0.22%)

Streaming Delayed Price Updated: 12:03 PM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Amylyx (AMLX) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

Amylyx (AMLX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Narrower-Than-Expected Q4 Loss, Focus Remains on Key 2026 Data ↗

March 03, 2026

Via Chartmill

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder ↗

August 27, 2025

Via Stocktwits

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million ↗

February 01, 2026

A Co-CEO of a leading neurotherapeutics developer reported significant insider selling amid a year of standout stock performance. But the sale is not what it seems.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Via The Motley Fool

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗

December 09, 2025

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

Via The Motley Fool

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗

December 09, 2025

A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.

Via The Motley Fool

Topics Regulatory Compliance

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Via The Motley Fool

Topics Regulatory Compliance

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Via The Motley Fool

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028 ↗

November 06, 2025

Amylyx Pharmaceuticals posts a narrower-than-expected Q3 2025 loss. The company bolsters its cash position, extending its runway into 2028 to fund its clinical pipeline.

Via Chartmill

US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target ↗

August 28, 2025

Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a...

Via Stocktwits

Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial ↗

August 27, 2025

Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting data in 2025 and 2026.

Via Benzinga

Amylyx (AMLX) Q2 Net Loss Narrows 43% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted ↗

August 07, 2025

Amylyx Pharmaceuticals reports Q2 2025 earnings with EPS in line, $41.4M net loss. Market reaction muted as focus remains on clinical-stage pipeline updates.

Via Chartmill

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery ↗

July 14, 2025

Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia.

Via Benzinga

Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial ↗

July 13, 2025

The company is advancing the treatment into a Phase 3 study with results expected in 2026.

Via Stocktwits

Why Shares in Amylyx Pharmaceuticals Soared This Week ↗

June 27, 2025

Via The Motley Fool

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market ↗

June 24, 2025

Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity.

Via Benzinga

Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday ↗

June 24, 2025

Via Benzinga

This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday ↗

June 24, 2025

Via Benzinga

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday ↗

June 24, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.